Joint Letter by the European Commission, EMA and HMA
A joint letter by the European Commission, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) is published on 03 July 2019.
Relevant protocol and results related information regarding clinical trials that are authorised in the EU needs to be kept in the EU Clinical Trials Database (EudraCT) and publicly available through the EU Clinical Trials Register. In order to improve compliance on the posting of results, the primary aim of this communication is to remind all sponsors about their obligation for the reporting of clinical trial summaries in the EU Clinical Trials Database.
The joint letter is available here.